Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v9-FR | Version v1-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2022-11-10 | 2022-09-13 |
| Drug Identification Number | 02243835 | 02243835 |
| Brand name | ARGATROBAN | ARGATROBAN |
| Common or Proper name | ARGATROBAN | ARGATROBAN |
| Company Name | SANDOZ CANADA INCORPORATED | SANDOZ CANADA INCORPORATED |
| Ingredients | ARGATROBAN | ARGATROBAN |
| Strength(s) | 100MG | 100MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 1LIVI | 1LIVI |
| ATC code | B01AE | B01AE |
| ATC description | ANTITHROMBOTIC AGENTS | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2022-11-01 | 2022-11-01 |
| Actual start date | ||
| Estimated end date | 2023-03-31 | 2023-03-31 |
| Actual end date | ||
| Shortage status | Actual shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Health Canada has permitted Sandoz Canada the exceptional, temporary importation and sale of a foreign product to provide an alternative treatment option during this critical shortage period. For more details visit: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages/list.html or contact Sandoz Canada Inc. Important information: Due to increase of demand, France-labelled Arganova product is currently distributed with restrictions but a replenishment is expected at the end of Dec-2022 and should allow the removal of the ordering restriction measure. | Sandoz Canada is presently making all efforts to avoid or limit the shortage situation including the increase of inventory level of alternative antithrombotic agents and searching for an alternative foreign source of the equivalent product as interim solutions. |
| Health Canada comments |